EP08.02-167 Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters

Abstract

The role of osimertinib in the first-line treatment for metastatic non-small cell lung cancer (NSCLC) has been established by FLAURA study. Acquired resistance would inevitably occur even with initially well response. Most acquired resistance were limited progression or oligo progression. Radiotherapy played important role in the era of first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) (gefitinib, erlotinib), while the role of radiotherapy in the era of third-generation EGFR TKIs was unknown.